• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Certara Inc.

    3/28/25 5:13:10 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CERT alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001827090
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Certara, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Certara, Inc.
    Street Address 1 Street Address 2
    4 RADNOR CORPORATE CENTER SUITE 350
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    RADNOR PENNSYLVANIA 19087 412-237-8272

    3. Related Persons

    Last Name First Name Middle Name
    Feehery William
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    CEO and Director
    Last Name First Name Middle Name
    Spaight David
    Street Address 1 Street Address 2
    4 Radnor Cororate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Walsh Matthew
    Street Address 1 Street Address 2
    4 Radnor Cororate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Gallagher III John
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    SVP and Chief Financial Officer
    Last Name First Name Middle Name
    Aspbury Robert
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    President, Certara Predicitive Technologies
    Last Name First Name Middle Name
    Pedersen Leif
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    President, Chief Commercial Officer
    Last Name First Name Middle Name
    McKemey Adrian
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    President, Certara Drug Development Solutions
    Last Name First Name Middle Name
    Corcoran Daniel
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    SVP and General Counsel
    Last Name First Name Middle Name
    Anhalt Rona
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Human Resources Officer
    Last Name First Name Middle Name
    Cashman James
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chairman of the Board
    Last Name First Name Middle Name
    Broshy Eran
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Collins Cynthia
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Crane Rosemary
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Killefer Nancy
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    McLean Stephen
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Reynders John
    Street Address 1 Street Address 2
    4 Radnor Corporate Center Suite 350
    City State/Province/Country ZIP/PostalCode
    Radnor PENNSYLVANIA 19087
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
    X Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-03-24    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
    X Yes    No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount USD
    or X Indefinite
    Total Amount Sold $5,670,000 USD
    Total Remaining to be Sold USD
    or X Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    6

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Certara, Inc. /s/ Daniel D. Corcoran Daniel D. Corcoran SVP and General Counsel 2025-03-28

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $CERT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERT

    DatePrice TargetRatingAnalyst
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    2/27/2025$16.00Buy
    TD Cowen
    9/27/2024$16.00Neutral → Buy
    UBS
    4/10/2024$23.00Sector Weight → Overweight
    KeyBanc Capital Markets
    4/4/2024Mkt Perform
    JMP Securities
    2/26/2024$19.00Market Perform
    Leerink Partners
    12/7/2023$17.00Neutral
    UBS
    12/5/2023Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $CERT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Certara upgraded by Barclays with a new price target

      Barclays upgraded Certara from Equal Weight to Overweight and set a new price target of $14.00

      5/8/25 8:23:49 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • TD Cowen initiated coverage on Certara with a new price target

      TD Cowen initiated coverage of Certara with a rating of Buy and set a new price target of $16.00

      2/27/25 6:17:48 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara upgraded by UBS with a new price target

      UBS upgraded Certara from Neutral to Buy and set a new price target of $16.00

      9/27/24 7:31:50 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Leadership Updates

    Live Leadership Updates

    See more
    • Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

      RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

      3/5/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Appoints John Reynders as New Independent Board Member

      RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&

      10/16/24 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • MaxCyte Appoints Cynthia Collins to its Board of Directors

      ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

      10/15/24 8:05:00 AM ET
      $CERT
      $MXCT
      $PSTX
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CERT
    Financials

    Live finance-specific insights

    See more
    • Certara Reports First Quarter 2025 Financial Results

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t

      5/5/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

      Reiterates Full-Year 2025 GuidanceArsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $100 million of its outstanding common stock. "We are pleased with our first quarter performance, driven by strong commercial execution and demand for our software and services," said

      4/14/25 8:00:00 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Reports Fourth Quarter 2024 Financial Results

      RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 26%.Services revenue was $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%. Net income was $6.6 million, compared to a net loss of $12.5 million in the fourth quarter of 2023.Adjuste

      2/26/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Certara Reports First Quarter 2025 Financial Results

      RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t

      5/5/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara to Participate in Upcoming Investor Conferences

      RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare ConferenceDate and Time: Tuesday, May 13 at 3:40 p.m. PT William Blair 45th Annual Growth Stock ConferenceDate and Time: Wednesday, June 4 at 12:40 p.m. CT Live webcasts for each of the conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates medicines using biosimulation software, technology, and

      4/29/25 4:15:00 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

      RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies. The Roadmap marks a pivotal moment in drug development. Companies that act now can future-proof their portfolios, gaining competitive advantage through faster timelines, lower costs, and stronger predictive evidence. Globally, there are thousands of monoclonal antibodies and antibody-drug conjugates (ADCs) currently in the preclinical phase of devel

      4/14/25 8:15:00 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Certara Inc.

      SC 13G - Certara, Inc. (0001827090) (Subject)

      11/14/24 8:38:56 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SC 13G/A filed by Certara Inc.

      SC 13G/A - Certara, Inc. (0001827090) (Subject)

      10/4/24 10:25:50 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Certara Inc. (Amendment)

      SC 13G/A - Certara, Inc. (0001827090) (Subject)

      2/13/24 5:01:03 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Certara Inc.

      10-Q - Certara, Inc. (0001827090) (Filer)

      5/5/25 4:31:57 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Certara Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Certara, Inc. (0001827090) (Filer)

      5/5/25 4:24:47 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SCHEDULE 13D/A filed by Certara Inc.

      SCHEDULE 13D/A - Certara, Inc. (0001827090) (Subject)

      4/14/25 5:15:03 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT, PREDICTIVE TECH Aspbury Robert was granted 7,082 shares, covered exercise/tax liability with 15,846 shares and converted options into 26,626 shares, increasing direct ownership by 6% to 307,176 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      4/3/25 4:44:38 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • PRESIDENT, CHIEF COMMERCAL OFF Pedersen Leif E was granted 7,082 shares, covered exercise/tax liability with 8,209 shares and converted options into 26,626 shares, increasing direct ownership by 26% to 125,203 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      4/3/25 4:40:25 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • PRESIDENT, CHIEF COMMERCAL OFF Gallagher John E converted options into 42,486 shares and covered exercise/tax liability with 14,176 shares, increasing direct ownership by 155% to 46,528 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      4/3/25 4:36:31 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology